SAN FRANCISCO, October 30, 2018 /PRNewswire/ --
The global urothelial cancer drugs market size is expectedto reach USD 3.6 billion by 2023, as per a new report by Grand View Research, Inc., exhibiting a 22.9% CAGR during the forecast period. Availability of novel drugs, presence of a strong pipeline, rising disease incidence,
(Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )
Urothelial cancer is the ninth most common malignancy in the world, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Approximately 59% of bladder cancer cases occur in developed regions such as North America and Europe. The disease has the highest lifetime cost of care per patient among all tumors in U.S. due to its high relapse rate and invasive lifelong monitoring including cystoscopy follow-ups.
Bladder transitional cell carcinoma (TCC) is the most common histology, accounting for nearly 90% of all urinary cancer cases. Urothelial cancer is clinically divided into three categories: non-muscle invasive bladder cancer (NMIBC, early stage), muscle invasive disease (MIBC, mid stage), and metastatic disease (late stage). At diagnosis, approximately 70% of cases are non-muscle invasive disease, 20% are at the muscle invasive stage, and 10% are at the advanced stage.
Browse full research report with TOC on "Urothelial Cancer Drugs Market Size, Share & Trends Analysis Report By Treatment Class (Chemotherapy, Immunotherapy), By Major Markets, Competitive Landscape, And Segment Forecasts, 2018 - 2023" at: https://www.grandviewresearch.com/industry-analysis/urothelial-cancer-drugs-market
Further Key Findings From the Report Suggest:
Browse related reports by Grand View Research:
Grand View Research has segmented the global urothelial cancer drugs market based on treatment class and country:
Explore the BI enabled intuitive market research database, Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email: firstname.lastname@example.org
SOURCE Grand View Research, Inc.
Subscribe to our Free Newsletters!